Lars Henning Engelholm
7PUBLICATIONS
21CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Dec 10, 2025
Targeting uPARAP with an Antibody-Drug Conjugate Exhibits Efficacy against Mesothelioma and Synergizes with Cisplatin.Pınar Çakılkaya, Ida Marie Egeland Larsen, Qun Jiang
|Jul 16, 2025
The Recycling Collagen Receptor uPARAP Is a Unique Mediator of Stromal Drug Delivery to Carcinoma Cells.Kirstine S Nørregaard, Ida M E Larsen, Henrik J Jürgensen
|Jan 25, 2025
A HER2 Specific Nanobody-Drug Conjugate: Site-Selective Bioconjugation and In Vitro Evaluation in Breast Cancer Models.Anders H Hansen, Kasper I H Andersen, Li Xin
|Jan 17, 2025
Targeting uPAR with an antibody-drug conjugate suppresses tumor growth and reshapes the immune landscape in pancreatic cancer models.Virginia Metrangolo, Michaela Hansen Blomquist, Ananya Dutta
|Jan 26, 2024
Antibody-Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs.Virginia Metrangolo, Lars H Engelholm
|Nov 13, 2021
The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities.Virginia Metrangolo, Michael Ploug, Lars H Engelholm
Pageof 2
Frequent Collaborators
5 joint publications
Oliver Krigslund
4 joint publications
Henrik Jessen Jürgensen
4 joint publications
Henrik Gårdsvoll
4 joint publications
Virginia Metrangolo
3 joint publications
Pınar Çakılkaya
3 joint publications
Eric Santoni-Rugiu
3 joint publications
Niels Behrendt
3 joint publications
Kirstine Sandal Nørregaard
2 joint publications
Michael Ploug
2 joint publications
Ida Marie Egeland Larsen
